Cargando…

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis

OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Afshari, Daryoush, Moradian, Nasrin, Nasiri, Freshteh, Razazian, Nazanin, Bostani, Arash, Sariaslani, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Riyadh : Armed Forces Hospital 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727621/
https://www.ncbi.nlm.nih.gov/pubmed/26492115
http://dx.doi.org/10.17712/nsj.2015.4.20150375
_version_ 1782411990965157888
author Afshari, Daryoush
Moradian, Nasrin
Nasiri, Freshteh
Razazian, Nazanin
Bostani, Arash
Sariaslani, Payam
author_facet Afshari, Daryoush
Moradian, Nasrin
Nasiri, Freshteh
Razazian, Nazanin
Bostani, Arash
Sariaslani, Payam
author_sort Afshari, Daryoush
collection PubMed
description OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind clinical trial conducted between December 2013 and December 2014. The subjects were selected among patients referred to Neurology Department, Imam Reza Hospital; affiliated to Kermanshah University of Medical Sciences, Kermanshah, Iran. Fifty-two cases of CVST were included in this study and randomly divided into 2 groups. Twenty-six cases received LMWH and the other 26 cases received UFH. The primary outcomes include hospital mortality rate and neurologic deficits as assessed by the National Institutes of Health Stroke Scale (NIHSS). The secondary end point was disability as measured by the Modified Rankin Scale (MRS). RESULTS: We observed the rate of mortality and neurological deficits and disability based on NIHSS, and the MRS did not differ between the 2 groups. CONCLUSION: The efficacy of LMWH and UFH in reduction of neurologic deficit and functional disability in patients with CVST are similar.
format Online
Article
Text
id pubmed-4727621
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Riyadh : Armed Forces Hospital
record_format MEDLINE/PubMed
spelling pubmed-47276212016-02-02 The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis Afshari, Daryoush Moradian, Nasrin Nasiri, Freshteh Razazian, Nazanin Bostani, Arash Sariaslani, Payam Neurosciences (Riyadh) Original Article OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind clinical trial conducted between December 2013 and December 2014. The subjects were selected among patients referred to Neurology Department, Imam Reza Hospital; affiliated to Kermanshah University of Medical Sciences, Kermanshah, Iran. Fifty-two cases of CVST were included in this study and randomly divided into 2 groups. Twenty-six cases received LMWH and the other 26 cases received UFH. The primary outcomes include hospital mortality rate and neurologic deficits as assessed by the National Institutes of Health Stroke Scale (NIHSS). The secondary end point was disability as measured by the Modified Rankin Scale (MRS). RESULTS: We observed the rate of mortality and neurological deficits and disability based on NIHSS, and the MRS did not differ between the 2 groups. CONCLUSION: The efficacy of LMWH and UFH in reduction of neurologic deficit and functional disability in patients with CVST are similar. Riyadh : Armed Forces Hospital 2015-10 /pmc/articles/PMC4727621/ /pubmed/26492115 http://dx.doi.org/10.17712/nsj.2015.4.20150375 Text en Copyright: © Neurosciences https://creativecommons.org/licenses/by-nc-sa/3.0/Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.
spellingShingle Original Article
Afshari, Daryoush
Moradian, Nasrin
Nasiri, Freshteh
Razazian, Nazanin
Bostani, Arash
Sariaslani, Payam
The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title_full The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title_fullStr The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title_full_unstemmed The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title_short The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
title_sort efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727621/
https://www.ncbi.nlm.nih.gov/pubmed/26492115
http://dx.doi.org/10.17712/nsj.2015.4.20150375
work_keys_str_mv AT afsharidaryoush theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT moradiannasrin theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT nasirifreshteh theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT razaziannazanin theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT bostaniarash theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT sariaslanipayam theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT afsharidaryoush efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT moradiannasrin efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT nasirifreshteh efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT razaziannazanin efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT bostaniarash efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis
AT sariaslanipayam efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis